An Evaluation of Pyrisuccideanol Maleate (Nadex) in the Treatment of Mild to Moderate Depression in Patients Aged 55 Years and Over,Presenting in General Practice

Abstract

A randomized double-blind study was undertaken comparing the therapeutic efficacy of pyrisuccideanol maleate (Nadex) and placebo in sixteen general practices, involving a total of 100 patients presenting with mild to moderate depression. The trial duration period was 6 weeks with assessments being made initially, and at 4 and 6 weeks. A consistently higher proportion of those treated with Nadex demonstrated an improvement in their symptoms as compared to those treated with placebo and some of the differences proved to be statistically significant. Nadex was also observed to be well tolerated.